In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Corp.

Division of Bausch Health Companies Inc.
www.biovail.com

Latest From Biovail Corp.

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.

Appointments

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

BioPharmaceutical Policy

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

BioPharmaceutical Policy

Probes Drive Valeant To Fewer Price-Based Transactions

Valeant Pharmaceuticals International Inc. on Oct. 19 said the "turmoil" over its practices of buying up companies with older drugs and raising their prices has driven the company to change its strategy to seek fewer transactions focused on what it called "mispriced products."

See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register